MA53898B1 - Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament - Google Patents

Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament

Info

Publication number
MA53898B1
MA53898B1 MA53898A MA53898A MA53898B1 MA 53898 B1 MA53898 B1 MA 53898B1 MA 53898 A MA53898 A MA 53898A MA 53898 A MA53898 A MA 53898A MA 53898 B1 MA53898 B1 MA 53898B1
Authority
MA
Morocco
Prior art keywords
pyrazin
ylmethyl
medicine
morpholine derivatives
nr2b
Prior art date
Application number
MA53898A
Other languages
English (en)
Other versions
MA53898A (fr
Inventor
Riccardo Giovannini
Cornelia Dorner-Ciossek
Dieter Wiedenmayer
Angelo Ceci
Roland Pfau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA53898A publication Critical patent/MA53898A/fr
Publication of MA53898B1 publication Critical patent/MA53898B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouvelles 4-pyrazin-2-ylméthyl-morpholines de formule générale a, des procédés pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation en thérapie, en particulier dans le traitement ou la prévention d'états associés à des propriétés de modulation allostérique négative de nr2b.
MA53898A 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament MA53898B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (fr) 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament

Publications (2)

Publication Number Publication Date
MA53898A MA53898A (fr) 2022-01-26
MA53898B1 true MA53898B1 (fr) 2023-03-31

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53898A MA53898B1 (fr) 2018-10-17 2019-10-16 Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament

Country Status (36)

Country Link
US (2) US11166958B2 (fr)
EP (1) EP3867244B1 (fr)
JP (1) JP7093468B2 (fr)
KR (1) KR20210079325A (fr)
CN (1) CN112888685B (fr)
AR (1) AR116711A1 (fr)
AU (1) AU2019362330B2 (fr)
BR (1) BR112021004993A2 (fr)
CA (1) CA3113308A1 (fr)
CL (1) CL2021000858A1 (fr)
CO (1) CO2021004612A2 (fr)
CR (1) CR20210184A (fr)
DK (1) DK3867244T3 (fr)
DO (1) DOP2021000069A (fr)
EA (1) EA202191014A1 (fr)
EC (1) ECSP21027009A (fr)
ES (1) ES2940184T3 (fr)
FI (1) FI3867244T3 (fr)
HR (1) HRP20230249T1 (fr)
HU (1) HUE061891T2 (fr)
IL (1) IL282142B2 (fr)
JO (1) JOP20210075A1 (fr)
LT (1) LT3867244T (fr)
MA (1) MA53898B1 (fr)
MX (1) MX2021004418A (fr)
PE (1) PE20211278A1 (fr)
PH (1) PH12021550834A1 (fr)
PL (1) PL3867244T3 (fr)
PT (1) PT3867244T (fr)
RS (1) RS63988B1 (fr)
SA (1) SA521421756B1 (fr)
SG (1) SG11202103806VA (fr)
SI (1) SI3867244T1 (fr)
TW (1) TWI828779B (fr)
UA (1) UA128408C2 (fr)
WO (1) WO2020079039A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202112378A (zh) * 2019-06-04 2021-04-01 德商百靈佳殷格翰國際股份有限公司 嘌呤衍生物及其作為藥物之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
EP1390034A4 (fr) 2001-04-03 2005-07-13 Merck & Co Inc Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues
EP1409477B1 (fr) * 2001-07-24 2008-09-17 Richter Gedeon NYRT Derives de piperidine utilises en tant qu'antagonistes du recepteur n-methyl-d-aspartate (nmda)
CA2630517A1 (fr) * 2005-12-06 2007-06-14 Merck & Co., Inc. Antagonistes de recepteur de prokineticine de morpholine-carboxamide
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2012128582A2 (fr) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
AU2013333988B2 (en) * 2012-10-18 2017-03-09 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mGluR5 receptor activity
WO2015130905A1 (fr) 2014-02-27 2015-09-03 Merck Patent Gmbh Composés hétérocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations
WO2016029146A1 (fr) 2014-08-22 2016-02-25 University Of Washington Inhibiteurs spécifiques de la méthionyl-tarn synthétase
AU2016340239A1 (en) * 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists

Also Published As

Publication number Publication date
UA128408C2 (uk) 2024-07-03
IL282142B1 (en) 2023-12-01
MA53898A (fr) 2022-01-26
HUE061891T2 (hu) 2023-09-28
CA3113308A1 (fr) 2020-04-23
AU2019362330B2 (en) 2024-03-28
AR116711A1 (es) 2021-06-02
ES2940184T3 (es) 2023-05-04
KR20210079325A (ko) 2021-06-29
PE20211278A1 (es) 2021-07-19
JOP20210075A1 (ar) 2023-01-30
WO2020079039A1 (fr) 2020-04-23
BR112021004993A2 (pt) 2021-06-08
SI3867244T1 (sl) 2023-04-28
HRP20230249T1 (hr) 2023-04-14
CN112888685A (zh) 2021-06-01
EP3867244A1 (fr) 2021-08-25
DOP2021000069A (es) 2021-05-31
TW202031262A (zh) 2020-09-01
CN112888685B (zh) 2023-09-22
CL2021000858A1 (es) 2021-10-01
LT3867244T (lt) 2023-03-10
PH12021550834A1 (en) 2021-10-04
SG11202103806VA (en) 2021-05-28
IL282142B2 (en) 2024-04-01
EA202191014A1 (ru) 2021-11-09
FI3867244T3 (fi) 2023-03-20
JP2022505080A (ja) 2022-01-14
EP3867244B1 (fr) 2023-01-18
JP7093468B2 (ja) 2022-06-29
IL282142A (en) 2021-05-31
US20200121691A1 (en) 2020-04-23
AU2019362330A1 (en) 2021-04-08
PL3867244T3 (pl) 2023-05-22
CR20210184A (es) 2021-05-26
TWI828779B (zh) 2024-01-11
DK3867244T3 (da) 2023-05-01
RS63988B1 (sr) 2023-03-31
US11166958B2 (en) 2021-11-09
MX2021004418A (es) 2021-07-06
CO2021004612A2 (es) 2021-04-30
PT3867244T (pt) 2023-02-22
SA521421756B1 (ar) 2023-02-12
US20210393644A1 (en) 2021-12-23
ECSP21027009A (es) 2021-05-31

Similar Documents

Publication Publication Date Title
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
TN2014000147A1 (fr) Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA54231A (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA34308B1 (fr) Triazolopyridines substituées
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA38099A1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA35422B1 (fr) Imidazopyridazines amino-substituees
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA51020B1 (fr) Composés imidazopyridiniques et leur utilisation comme médicament
MA53898B1 (fr) Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques